UK drug major GlaxoSmithKline is to cut 12% of its US sales force as part of a scheme to save L700.0 million ($1.11 billion) a year by 2010, according to media reports. The UK firm is to eliminate 1,800 positions, some of which are vacant, moving some staff to its vaccines unit, for total lay-offs of around 1,000 employees. GSK will also re-organize its remaining workforce by treatment area, rather than by geographic region as before, in a bid to win over health care professionals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze